

SARS-CoV-2 vaccination with CoronaVac: seroconversion rate in healthcare workers after 40 days

Lucas Bochnia-Bueno,^{a,c} M.Sc; Sergio Monteiro De Almeida,^a PhD; Sonia Mara Raboni,^{a,c} PhD; Douglas Adamoski,^b PhD; Ludmilla Louise Moreira Amadeu^a; Suzana Carstensen;^a M.Sc, Meri Bordignon Nogueira,^{a*} PhD

^a Virology Laboratory, Federal University of Paraná, General Carneiro, 180, Curitiba, Brazil

^b Department of Genetics, Federal University of Paraná, Curitiba, PR, Brazil

^c Post-Graduate Program in Microbiology, Parasitology and Pathology, Federal University of Paraná, Curitiba, PR, Brazil

#Corresponding author:

Meri Bordignon Nogueira

R Padre Camargo, 280, Curitiba, Brazil

Zip Code: 80060-240

Phone: +55 41 3360-7974

E-mail: meribordignon.nogueira@gmail.com

Word counts:

Abstract

Background: This study aimed to calculate the seroconversion rate of the CoronaVac vaccine in healthcare workers (HCWs) 40 days after administration.

Methods: Serum samples from 133 HCWs from Southern Brazil were collected one day before (Day 0) and 10, 20, and 40 days after administering the vaccine's first dose. Immunoglobulin G (IgG) was quantified using immunoassays for anti-N-protein antibodies (Abbott, Sligo, Ireland) and for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany).

Results: Seroconversion by D 40 (20 days after the second dose) occurred in 129 (97%) HCWs for the S1 protein, and in 69 (51.87%) HCWs for the N protein. An absence of IgG antibodies (by both methodologies), occurred in two (1.5%) HCWs undergoing semiannual rituximab administration, and also in another two (1.5%) HCWs with no apparent reason.

Conclusion: This study showed that CoronaVac has a high seroconversion rate when evaluated in an HCW population.

Funding: This work was supported by the PROPLAN/Federal University of Paraná, Curitiba-Paraná, Brazil; FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 (0494/20).

Keywords: SARS-CoV-2, vaccine, immunization, public health, immunoglobulin G, CoronaVac, pandemic.

1. Introduction

By April 7, 2021, approximately one year after the beginning of the SARS-CoV-2 pandemic, confirmed cases of infection worldwide numbered 131,837,512 people, including 2,862,664 deaths¹. The race for an effective vaccine began as soon as this new human coronavirus was discovered in December 2019, with the efforts of many companies, researchers, and scientists around the world throughout 2020²⁻⁴. At the end of 2020, the first immunization doses reached the population; 604,032,357 doses of vaccine had been administered by April 5, 2021¹.

Worldwide efforts resulted in the development of several vaccines against SARS-CoV-2 with various distinct antigen delivery systems (non-replicating viral vector, protein subunit, inactivated virus, and mRNA)^{2,3}. As of April 2021, CoronaVac (Sinovac Life Sciences, Beijing, China) was the most administered in Brasil⁵, using the inactivated virus as a component of the vaccine^{2,3}. As the vaccine was administered across the complete range of ethnicities, comorbidities, and ages, phase I/II trial results may not perfectly reflect vaccine response times and seroconversion rates.

This study aimed to identify the seroconversion rate after vaccination with SARS-CoV-2 (CoronaVac) in healthcare workers (HCWs) 40 days after its application.

2. Methods

2.1 Participants

In total, 170 participants were recruited at the Complexo Hospital de Clínicas, UFPR, Clinical Laboratory, Curitiba, Brazil, during the vaccination of healthcare worker in this city. The Institutional Ethical Committee approved the study (CAAE: 31687620.2.0000.0096), and all participants signed their consent.

The inclusion criteria were as follows: answering the questionnaire, being vaccinated with two doses of CoronaVac, and providing serum samples. Fourteen participants were excluded because they did not complete the questionnaire. Seven participants took another vaccine, one participant did not have the second dose, and 15 participants did not provide a sample on days 0 or +40.

Serum samples of 133 healthcare workers included in this study were collected on days 0 (first dose application), +10, +20 (second dose application), and +40. All samples were stored at -20°C until analysis.

The participants were divided into two groups based on day 0 serology according to anti-spike-1 (anti-S1) immunoglobulin G (IgG)⁶⁻⁸: *reactive* (n=16) and *non-reactive* (n=117). The participants were also sorted according to the presence of comorbidities into two divisions: *probably immunosuppressed* (n=9) or *not* (n=124).

2.2 Seroconversion evaluation

Semi-quantitative assays were performed to detect anti-SARS-CoV-2 IgG. For all serum samples, assays used the Chemiluminescent Microparticle Immunoassay (CMIA) Architect-I System for anti-nucleocapsid protein (anti-N) IgG (Abbott, Sligo, Ireland). Additionally, for serum samples from days 0 and +40, assays used the Enzyme-Linked Immunosorbent Assay (EIA) for IgG anti-S1 spike-protein receptor-binding domain (RBD) (Euroimmun, Lübeck, Germany).

Samples were tested in duplicate, following the manufacturer's instructions. Results with a variation coefficient greater than 15.0% were repeated.

2.3 Statistical analysis

According to the distribution of seroconversion at day +40, the category variables were evaluated using Pearson's chi-squared test with Yates' continuity correction. The age variable was evaluated using the Wilcoxon signed rank sum test with continuity correction. Samples paired over time were evaluated using the Friedman ANOVA test (as implemented in the rstatix package), followed by the Wilcoxon signed rank test as a post-hoc pairwise comparison. For samples without multiple observations over time, the Wilcoxon signed rank test was used. All statistical analyses were performed using R (R Core Team).

3. Results

3.1 Seroconversion to S1 protein

Robust production of S1-protein IgG was observed by day +40 in 129 (97%) HCW participants (Figure 1B, D). Although the reactive and non-reactive groups had different values for S1-protein IgG on day 0 ($p < 0.0001$), on day +40, the average index between the groups was not significantly different ($p = 0.3704$).

3.2 Seroconversion to N protein

No significant production of the anti-N-protein IgG was observed in non-reactive group participants 10 days after the first vaccine dose ($p = 0.5027$; Figure 1A), and although there was a statistical difference in the sample on day +20 ($p < 0.0001$), there was no apparent seroconversion at that time. By contrast, there was a marked increase in N-protein IgG levels in 69 (51.87%) participants on day +40 (Figure 1A). A significant difference was also observed in the average index for this antibody between the reactive (Figure 1C) and non-reactive groups (Figure 1A): day 0 ($p < 0.0001$) and day +40 ($p = 0.0657$).

3.3 Combined response

In the non-reactive group, better-developed antibody responses were observed for N and S1 proteins ($p < 0.0001$; Figure 1A, B), while in the reactive group, the antibody response showed a significant difference ($p < 0.0001$) only for antibodies against S1 protein (Figure 1D), increasing the level of circulating humoral response. No significant alteration was observed in IgG anti-N protein analysis for the reactive group at days +10, +20, and +40 ($p = 0.2231$).

Comorbidities were reported by some HCWs, including Crohn's disease, prior bariatric surgery, HIV+, or diabetes (Table 1). In general, the participants with comorbidities responded to the vaccine similarly to participants without any comorbidities. However, two cases in the immunosuppressed group did not undergo seroconversion (Figure 2). Furthermore, two other HCWs (not in the immunosuppressed group) did not seroconvert by day +40; both had no apparent cause. This four HCWs without seroconversion were re-evaluated by a serum sample taken at +60 days. Of these, one participant presented seroconversion of the S1 protein (Figure 3).

In the anti-S1 reactive group on day 0, six (37.50%) participants did not have a previous SARS-CoV-2 diagnosis, possibly due to an asymptomatic infection. Furthermore, in the anti-S1 non-reactive group, 7 (5.98%) participants had symptoms suggestive of SARS-CoV-2, although we did not have information about nasopharyngeal RT-PCR or immunological rapid-test detection. Epidemiologic and clinical participant data are shown in Table 1.

4. Discussion

The seroconversion rate of 97% for the anti-S1 IgG observed in HCWs is important data for the scientific community, since in phase III studies of this and other vaccine candidates for SARS-CoV-2, similar or lower seroconversion rates were observed⁹.

However, several mutations in the RBD region of the S1 protein have produced new virus variants, as previously described: P.1, P.2, B.1.351, B.1.1.7, and B.1.325¹⁰⁻¹⁴. Such mutations confer the potential for the virus to escape the humoral immune response produced by the body due to the disease or to mRNA vaccines¹⁵. Thus, studies that evaluate vaccine efficacy against these new strains are valuable¹⁶.

Therefore, seroconversion rates observed for N-protein IgG could be valuable with the emergence of SARS-CoV-2 variants, considering the lower mutation levels in this protein⁸, compared to the high mutation levels in the S1 protein⁶. Therefore, seroconversion of N-protein antibodies may be an alternative for the vaccine industry to produce efficient vaccines for circulating strains, including those that may arise in the future.

Curiously, there was no difference in the analysis for the N-protein IgG in the reactive group, possibly due to the antibody levels present at day 0 in this group, the vaccine has not interfered in the humoral response; the group remained at the same average index. However, 5.98% of the participants in the group without seroconversion had previously contracted COVID-19, and that all of them presented seroconversion after the complete vaccination. Moreover, whether the person had experienced the disease or not, the levels of antibodies at day +40 post-vaccine were the same, giving the same level of protection. This finding agrees with Krammer et al. (2021) in a study of individuals with and without previous COVID-19, given the mRNA vaccine. This same response level implies the same antigen concentration, showing no difference in individual antibody response regardless of previous infection.

In participants with immunosuppressive treatment, the absence of the antibody response was probably due to rituximab having been administered approximately one month before the vaccine. In this situation, as described by Kado et al. (2016), B lymphocytes

are completely absent in the body. Consequently, there is no production of antibodies until the B lymphocytes recover in 6 to 24 months. In such cases, the response must be evaluated after the repletion time, and re-vaccination considered with medical and clinical endorsement. Of the other two cases lacking seroconversion at day +40, one participant presented seroconversion on day +60: a late response. The only unexplained case of no seroconversion should be further studied to understand what interfered with the immune response.

The immune response developed by vaccination depends not simply on antibodies, but largely on neutralizing antibodies¹⁹. Both natural infection and vaccination act on the immune system in complex ways, stimulating the production of non-neutralizing antibodies (with their own specific actions) as well as TCD4⁺ and TCD8⁺ T cells, which also act to protect against COVID-19, as shown by Tarke et al. (2021). That study evaluated the immune response to the SARS-CoV-2 variants, and showed that cellular immunity-unlike the humoral response is little affected by the virus variants. In addition to the specific immune response, innate immunity is another important protection mechanism against infections¹⁹.

The present study has some limitations: the humoral immunity was studied semi-quantitatively, there was no quantification and titration of anti-SARS-CoV-2 antibodies, and no testing for neutralizing antibodies. The total number of participants was small, and immunosuppressed comorbidities were low in number and had diverse etiologies. More studies are needed to elucidate the vaccine response in these specific groups. However, this is the first study to evaluate the dynamics of IgG production after CoronaVac immunization in the community.

The results of seroconversion have shown the importance of two doses for this vaccine as, until the second dose was applied, there was no change in the production of N-

protein IgG, as previously described by Zhang et al. (2021) in phase I/II tests for this vaccine, with the antibody response detectable just 14 days after the second dose. The second vaccine dose is important for several types of vaccines, including mRNA vaccines, as described by Dörschug et al. (2021), resulting in a significant increase in antibody levels. Therefore, with SARS-CoV-2, there would be no difference at this point.

In conclusion, significant antibody production was observed 40 days after the first CoronaVac dose in the large majority of study participants, independent of comorbidities. The anti-N protein and anti-S1 protein antibody responses of participants without prior SARS-CoV-2 infection were comparable with those of the previously infected group, in which the immune response was maintained or optimized, with no decrease in levels. However, more studies are necessary to draw conclusions.

Acknowledgments

The authors would like to thank all participants who agreed to participate in this study, those involved in the collection and storage of samples, and the Immunochemistry Laboratory section of Complexo Hospital de Clínicas, UFPR, and CAPES.

Conflict of interest

The authors declare that there is no conflict.

References

- 1 World Health Organization (WHO), WHO Coronavirus (COVID-19) Dashboard. [cited 2021 Apr 7] Available from: <https://covid19.who.int/>
- 2 Golob JL, Lugogo N, Luring AS, Lok AS. SARS-CoV-2 vaccines: a triumph of science and collaboration. *JCI Insight*. 2021 Apr 6;

- 3 Kumar SU, Priya NM, Priyanka SRN, Nikita K, Thirumal JD. A review of novel coronavirus disease (COVID □ 19): based on genomic structure , phylogeny , current shreds of evidence , candidate vaccines , and drug repurposing. 3 Biotech. 2021;
- 4 Castro MC, Singer B. Prioritizing COVID-19 vaccination by age. Proc Natl Acad Sci U S A. 2021 Apr 13;118(15).
- 5 Brasil, Ministério da Saúde, COVID-19 Vacinação Doses Aplicadas. [cited 2021 Apr 7] Available from: https://viz.saude.gov.br/extensions/DEMAS_C19Vacina/DEMAS_C19Vacina.html
- 6 Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Front Immunol. 2021;12(March):1–12.
- 7 Zeng W, Liu G, Ma H, Zhao D, Yang Y, Liu M, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527(3):618–23.
- 8 Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. J Virol. 2020;94(13):1–2.
- 9 Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? Adv Drug Deliv Rev [Internet]. 2021;172. Available from: <https://doi.org/10.1016/j.addr.2021.01.014>
- 10 Faria NR, Claro IM, Candido D, Franco LAM, Andrade PS, Coletti TM, et al. Genomic characterization of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological; 2021 January [cited 2021 Apr 7]. Available

from: <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manauas-preliminary-findings/586>

- 11 Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. *Virological*; 2020 December [cited 2021 Apr 7]. Available from: <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>
- 12 Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet*. 2021;397(10273):452–5.
- 13 Claro IM, da Silva Sales FC, Ramundo MS, Candido DS, Silva CAM, de Jesus JG, et al. Local Transmission of SARS-CoV-2 Lineage B.1.1.7, Brazil, December 2020. *Emerg Infect Dis* [Internet]. 2021 Mar;27(3):970–2. Available from: https://wwwnc.cdc.gov/eid/article/27/3/21-0038_article.htm
- 14 Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv*. 2020;2.
- 15 Garcia-beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *medRxiv*. 2021;
- 16 Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N

- Engl J Med. 2021;1–14.
- 17 Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* [Internet]. 2021 Apr 8;384(14):1372–4. Available from: <http://www.nejm.org/doi/10.1056/NEJMc2101667>
 - 18 Kado R, Sanders G, Joseph McCune W. Suppression of normal immune responses after treatment with rituximab. *Curr Opin Rheumatol*. 2016;28(3):251–8.
 - 19 Tarke A, Sidney J, Methot N, Zhang Y, Dan JM, Goodwin B, et al. Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees. *bioRxiv* [Internet]. 2021; Available from: <https://doi.org/10.1101/2021.02.27.433180>
 - 20 Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*. 2021;21(2):181–92.
 - 21 Dörschug A, Frickmann H, Schwanbeck J, Yilmaz E, Mese K, Hahn A, et al. Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays. *Diagnostics*. 2021;11(3):426.

Figure 1: Antibody rates in the S1-protein IgG seroconverted/not seroconverted groups at day 0. Boxplot graph presents median (line dividing the box), interquartile range (box), maximum value (line above the box) and minimum value (line below the box). The line connecting the boxes represents the trend of the data. The dotted line represents the days of the vaccine application (two doses). **A** - N-protein IgG evaluation in S1-antibody nonreactive participants at day 0. **B** - S1-protein IgG evaluation in S1-protein IgG nonreactive participants at day 0. **C** - N-protein IgG evaluation in S1-protein IgG reactive participants at day 0. **D** - IgG anti-S1 protein evaluation in anti-S1 protein IgG reactive participants at day 0.

Figure 2: Antibody rates for participants *probably immunosuppressed* and *not*. White boxes indicate participants not probably immunosuppressed. Gray boxes indicate probably immunosuppressed participants. **A** - S1-protein IgG evaluation. **B** - N-protein IgG evaluation.

Figure 3: Antibody rates for participants without detected seroconversion at day +40. Purple and green lines represent the participants with Rituximab treatment. The dotted line represents the days of the vaccine application (two doses). **A** - N-protein IgG evaluation. **B** - S1-protein IgG evaluation.



Table 1: Clinical and epidemiological characteristics of participants included in the study for each respective group. Information on the handling of special cases: two immunosuppressed (Rituximab 1400 mg/semiannually), one myasthenia gravis (Pyridostigmine 120 mg/day), one Crohn's disease ostomized twenty-two years ago (Azathioprine 100 mg/day), two participants with prior bariatric surgery (11 and 12 years), and one HIV+ (Tenofovir 300 mg, Lamivudine 300 mg + Dolutegravir 50 mg/day; CD4⁺ 541/ μ L). *Comorbidities (probably immunosuppressed) included: Immunosuppressive drugs use, Crohn's disease, Previously bariatric surgery, HIV and

Diabetes. The patient with Myasthenia gravis is not included here because the treatment used was not immunosuppressive.



Table 1:


	IgG Anti-S1 (pre vaccine)		<i>p</i> value	Comorbidities probably immunosuppressed*		<i>p</i> value
	Reactive n (%)	Non-reactive n (%)		With n (%)	Without n (%)	
Total	16	117		9	124	
Female	13 (81.25)	93 (79.49)	1.0000	6 (66.67)	100 (80.64)	0.5636
Median Age (IQR)	44 (25.25 -52.75)	49 (39.50 - 53.50)	0.2225	51 (45.50 - 54.50)	48 (38.25 - 53.75)	0.2297

Without IgG anti-S1 (pre-vaccine)



With IgG anti-S1 (pre-vaccine)



A**B**